Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood vessel cells in a simple blood test may predict ovarian cancer therapy success

NCT ID NCT07807683

Knowledge-focused Sponsor: Centro di Riferimento Oncologico - Aviano Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study asks whether measuring circulating endothelial cells (CECs), cells shed from blood vessel walls, can predict how well ovarian cancer patients respond to standard chemotherapy with or without bevacizumab. Researchers will use a standardized flow cytometry method to count CECs in blood samples from 148 participants, including healthy donors and ovarian cancer patients, at baseline and after treatment. They will also look at microRNA levels in blood and tumor tissue. The goal is to find a reliable biomarker that helps doctors choose the right treatment for each patient, avoiding unnecessary side effects from costly therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood test measuring circulating endothelial cells and microRNAs
What this could lead to
If CEC levels reliably predict who benefits from anti-angiogenic therapy, doctors could tailor ovarian cancer treatment, sparing some patients from unnecessary side effects.
What could go wrong
This is an observational biomarker study, not a treatment trial. CEC measurement variability across labs has limited its use before, and the link to outcomes may not hold up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

148 people

The number who actually took part.

Started

Jan 2014

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy donors and consecutive ovarian cancer patients

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Healthy Donors: * Healthy adults caucasian female * Non-smoker * Normal blood pressure values * Normal complete blood count (CBC) * Normal blood chemistry values Inclusion Criteria for Cancer Patients: * Caucasian * Patients with confirmed histological diagnosis of ovarian carcinoma (all histotypes) * Treatment-naive or with disease recurrence occurring more than 12 months after the start of therapy * Normal systolic and diastolic blood pressure values, no cardiovascular comorbidities * Written informed consent Exclusion Criteria: Exclusion Criteria for Healthy Donors: * Diabetes * Hypertension * Active infectious states or chronic inflammatory diseases * Active or previous malignancies * Pharmacological treatment completed less than 48 hours prior * Statin treatment * Endometriosis * Cardiovascular disease / Heart disease * End of menstrual cycle less than 15 days prior * Non-fasting subjects * Obesity * Hypercholesterolemia * Active gastric or duodenal ulcer * Positive serology for HIV, Hepatitis A, B, or C infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

More trials for these conditions

Other studies related to the condition(s) this trial covers.